WCN26-5615 A 6-WEEK TREATMENT WITH SEMAGLUTIDE IMPROVES BOTH KIDNEY DYSFUNCTION AND HEART FAILURE WITH PRESERVED EJECTION FRACTION IN THE SDT FATTY RAT MODEL

Read full text Summarise with VIRAT
Authors: François Briand, Guillaume Bourdier, E. Grasset, Rana Assaly, Caroline Dubroca, Masami Shinohara, Thierry Sulpice
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The high prevalence of cardiovascular-kidney-metabolic (CKM) syndrome in the population requires novel therapeutics to reduce cardiovascular death, and to this aim, predictive animal models are needed. Here we evaluated the effects of the GLP-1 receptor agonist semaglutide on kidney dysfunction and heart failure with preserved ejection fraction (HFpEF) in the Spontaneously Diabetic Torii (SDT) fatty, as a type 2 diabetic rat model of CKM syndrome.

Fields of Study & Subjects

Diabetes Treatment and Management Heart Failure Treatment and Management Chronic Kidney Disease and Diabetes

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104481–104481
Publication date
25 March 2026
Language
EN